股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 第 1 頁 共 10 頁 v 1.1.1 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 錦欣生殖醫療集團有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | ...

Investment Rating - The report maintains an "OUTPERFORM" rating for Jinxin Fertility with a target price of HK$3.06, down 17.3% from previous estimates [2][6]. Core Insights - The company's revenue for 1H25 was RMB 1.29 billion, reflecting a year-on-year decline of 10.7%. Domestic business revenue was RMB 0.99 billion, down 13.4%, primarily due to a high base effect and the adaptation period to new medical insurance policies [3][12]. - The overseas business remained flat at RMB 0.30 billion, impacted by disruptions from California wildfires and delays in the implementation of the SB-729 policy, which mandates IVF coverage in large-group health plans [4][13]. - The gross margin decreased to 30.4%, down 10.0 percentage points, due to the zero-mark-up drug policy in Chengdu and other operational challenges. The company reported a net loss of RMB 1.04 billion, compared to a profit of RMB 0.19 billion in 1H24 [5][14]. - Adjusted net profit for 1H25 was RMB 82.3 million, a decrease of 68.3%, with an adjusted net margin of 6.4% [5][15]. - Revenue forecasts for 2025 and 2026 have been revised to RMB 2.83 billion and RMB 3.04 billion, reflecting slower-than-expected uptake of domestic IVF services and ongoing operational challenges [6][16]. Summary by Sections Financial Performance - Revenue for 1H25 was RMB 1.29 billion, down 10.7% year-on-year. Domestic revenue was RMB 0.99 billion, down 13.4%, while overseas revenue was flat at RMB 0.30 billion [3][12][13]. - The company reported a net loss of RMB 1.04 billion, primarily due to impairments and operational challenges [5][15]. Earnings Forecast - The revenue forecast for 2025 is RMB 2.83 billion, reflecting a growth of 0.7%, and for 2026, it is RMB 3.04 billion, reflecting a growth of 7.2% [6][16]. - Adjusted net profit is expected to be RMB 0.18 billion in 2025 and RMB 0.31 billion in 2026, with significant adjustments made due to various operational impacts [6][16]. Valuation - The target price has been adjusted to HK$3.06 based on a 25x price-to-earnings ratio for 2026, indicating a potential recovery in margins on a low base [6][16].

Core Viewpoint - The company reported disappointing financial results for 1H25, with a significant decline in revenue and adjusted net profit, primarily due to policy impacts and operational challenges [1][2]. Financial Performance - Revenue for 1H25 was 1.289 billion yuan, a year-on-year decrease of 10.7% [1]. - Adjusted net profit fell to 82 million yuan, down 67.0% year-on-year, which was below market expectations [1]. - The company incurred a net loss of 1.04 billion yuan, largely due to impairment losses on goodwill and intangible assets in the U.S. HRC segment [2]. Development Trends - The company anticipates a recovery in 2026 as the impact of new insurance policies stabilizes and patient volumes return to IVF treatments [1]. - The shift in the proportion of artificial insemination (IUI) cycles has temporarily affected average transaction prices and profit margins [1]. - The company plans to relocate its Shenzhen facility, which is expected to increase capacity and improve revenue and profit recovery [1]. Strategic Focus - The company is focusing on risk release, cash flow recovery, and enhancing shareholder returns through asset management and business restructuring [2]. - There is an expectation of continued supportive policies for fertility, which may boost the overall growth of the assisted reproductive industry [3]. - The company is exploring new growth opportunities in egg freezing services, which have strong customer retention and longer service cycles [3]. Profit Forecast and Valuation - The adjusted net profit forecasts for 2025 and 2026 have been reduced by 59.9% and 7.5% to 170 million yuan and 417 million yuan, respectively [3]. - The current stock price corresponds to adjusted P/E ratios of 47.58 and 20.80 for 2025 and 2026 [3]. - The company maintains an "outperform" rating with a target price of 3.90 HKD, indicating a potential upside of 25.0% from the current closing price [3].

Core Viewpoint - The report from交银国际 indicates that锦欣生殖(01951) experienced a significant decline in revenue and net loss in the first half of the year, prompting a downward revision of revenue and profit forecasts for the coming years [1] Financial Performance - Revenue decreased by 11% to 1.29 billion RMB in the first half of the year [1] - Net loss amounted to 1.04 billion RMB [1] - Gross margin fell by 10 percentage points to 30.4% [1] - Adjusted net profit was approximately 82 million RMB, representing a 68% year-on-year decline [1] Forecast Adjustments - Revenue forecasts for 2025 to 2027 have been reduced by 17% to 18% [1] - Adjusted net profit predictions have been cut by about 50% [1] - Target price has been lowered to 3.3 HKD, with the rating downgraded to "neutral" [1] Management Plans - Management's reform plans include restructuring and financing for the US business, halting further investments in Laos to optimize the debt structure and reduce financial costs [1] - Plans for share buybacks and dividends will be considered at appropriate times [1] - Focus will be on key domestic businesses, with a new Shenzhen facility relocation set to begin in the first quarter of next year [1] - The incubation facilities in Yunnan and Wuhan are expected to exceed 5,000 cycles in the short term, with improved profitability [1] - Strategic layout for fertility preservation business is also planned [1]

Core Viewpoint - The report from CMB International indicates that Jinxin Fertility (01951) experienced a significant decline in revenue and net loss in the first half of the year, prompting a downward revision of revenue and profit forecasts for the coming years [1] Financial Performance - Jinxin Fertility's revenue decreased by 11% to 1.29 billion RMB in the first half of the year [1] - The company reported a net loss of 1.04 billion RMB, with a gross margin decline of 10 percentage points to 30.4% [1] - After adjusting for impairment and other non-recurring or non-cash items, the adjusted net profit for the first half was approximately 82 million RMB, representing a year-on-year decline of 68% [1] Forecast Adjustments - CMB International has lowered the company's revenue forecasts for 2025 to 2027 by 17% to 18% [1] - The adjusted net profit forecast has been reduced by approximately 50% [1] - The target price for Jinxin Fertility has been revised down to 3.3 HKD, with the rating downgraded to "Neutral" based on current valuation [1] Management Plans - The management's reform plans include restructuring and financing for the U.S. business, halting further investments in Laos to optimize the debt structure and reduce financial costs [1] - There are plans for share buybacks and dividends at an appropriate time [1] - The company aims to focus on key domestic businesses, with a new hospital relocation in Shenzhen set to start in the first quarter of next year [1] - The incubation centers in Yunnan and Wuhan are expected to exceed 5,000 cycles in the short term, with improved profitability [1] - Strategic layout for fertility preservation business is also part of the management's future plans [1]

Group 1: Macro Insights - Industrial enterprises' profits continued to improve, with July's profit decline narrowing to 1.5% year-on-year from 4.3% in June, driven by a significant rebound in the computer and electronics sector [2] - The revenue growth rate for industrial enterprises slightly decreased to 1.1% in July from 1.6% in June, reflecting a slowdown in industrial production and investment growth [2] - The adjusted profit margin increased to 5.3% in July from 5.2% in June, indicating early effects of anti-involution policies on prices [2] Group 2: Fixed Income and Asset Comparison - Domestic equities showed a relative advantage over bonds, although this advantage has decreased recently; A-shares remain undervalued compared to historical levels [3] - The Hong Kong stock market has lagged behind A-shares, potentially benefiting from liquidity differences following the Fed's dovish stance [3] - In the context of a rate-cutting cycle, small-cap and cyclical sectors in the U.S. may perform relatively well, while leading tech stocks are expected to remain a long-term focus [3] Group 3: Consumer and Technology Insights - The "AI+" initiative is expected to drive significant changes in the technology consumption sector, with a focus on smart hardware and infrastructure [4][6] - Recommended investment areas include AI hardware such as smart glasses and robotic vacuum cleaners, with specific companies highlighted for potential growth [4] - The upcoming Meta Connect conference is anticipated to showcase new AI/AR glasses, indicating a growing interest and investment in this product category [5] Group 4: Company Performance Highlights - YTO Express reported a revenue of 35.88 billion yuan for H1 2025, a year-on-year increase of 10.2%, but a net profit decline of 7.9% due to intense price competition in the express delivery sector [7] - Wuliangye's H1 2025 revenue reached 52.77 billion yuan, with a net profit increase of 2.3%, despite facing challenges in the second quarter [7] - Shanxi Coal Industry's H1 2025 revenue was 77.98 billion yuan, down 14.19% year-on-year, with a net profit decline of 31.18%, primarily due to falling coal prices [9] Group 5: Sector-Specific Developments - The AI application wave is expected to accelerate following the release of a national guideline on AI, marking a shift towards deeper integration with the real economy [6] - The food and beverage sector is seeing a shift in consumer preferences, with companies like Baoli Foods reporting stable performance amid competitive pressures [12] - The energy sector, particularly coal, is anticipated to benefit from potential Fed rate cuts, supporting cash flow stability for leading companies [9][27]

Group 1: Fourth Paradigm - The company is expected to achieve profitability in 2025, driven by increased demand for AI productivity in traditional industries [1] - Revenue forecasts for 2025-2027 have been raised by 7-22%, with a projected annual growth rate of 30% until 2029, reaching a revenue scale of 20 billion [1] - The target price has been adjusted to HKD 81, reflecting a potential upside of 27.6% [1] Group 2: Xianzhai AI Platform - The company reported a revenue of 2.626 billion, with a year-on-year growth of 40.7%, and the Xianzhai AI platform revenue grew by 71.9% [2] - The gross margin decreased to 37.7% compared to 42.7% for the full year of 2024, primarily due to an increase in sales of integrated hardware and software solutions [2] - The expense ratio improved to 45%, down from 50% in 2024, indicating ongoing operational efficiency [2] Group 3: Huanyou Group - The company exceeded profit expectations in Q2, with a revenue of 510 million, showing a 3% quarter-on-quarter recovery [3] - The adjusted net profit reached 77 million, surpassing the expected 63 million [3] - The advertising business is expected to continue driving incremental growth [3] Group 4: Kangfang Bio - The company achieved positive results in the HARMONi-A study, which is expected to enhance its commercial landscape due to insurance coverage [7] - The commercial sales revenue for the first half of 2025 grew by 49% to 1.4 billion, driven by key products included in the insurance directory [8] - The target price has been raised to HKD 183, reflecting a strong outlook for the company's products [8] Group 5: Jinxin Reproductive - The company faced significant performance pressure in the first half of 2025, with a revenue decline of 11% to 1.29 billion and a net loss of 1.04 billion [9] - The management plans to restructure the U.S. business and focus on key domestic operations to improve financial performance [10] - The target price has been lowered to HKD 3.30, reflecting a more cautious outlook [10] Group 6: Anta - The company reported a 14.3% year-on-year revenue growth in the first half of 2025, reaching 38.54 billion [11] - The overall gross margin decreased slightly to 63.4%, influenced by deeper discounts and a higher proportion of online sales [11] - The target price has been raised to HKD 117.90, indicating a positive long-term outlook [12] Group 7: Shenzhou International - The company experienced a 15.3% revenue growth in the first half of 2025, totaling 14.97 billion [13] - The gross margin recorded 27.1%, down 1.9 percentage points year-on-year, primarily due to rising labor costs [13] - The target price has been adjusted to HKD 84.00, reflecting a conservative outlook on profitability [14] Group 8: Ping An Insurance - The company reported a 3.7% year-on-year growth in operating profit, while net profit declined by 8.8% due to lower investment income [15] - New business value increased by 39.8%, exceeding expectations, primarily driven by the bancassurance channel [15] - The target price remains at HKD 73, indicating an attractive valuation [16] Group 9: China Resources Land - The company saw a 20% year-on-year revenue increase in the first half of 2025, reaching 94.9 billion [17] - The overall gross margin improved by 1.7 percentage points to 24%, with a core profit decline of 6.6% [17] - The target price has been raised to HKD 35.30, reflecting a positive outlook on profitability [18] Group 10: CIMC Enric - The company reported a 15.6% year-on-year increase in profit for the first half of 2025, totaling 560 million [19] - The clean energy segment saw a revenue increase of 22%, while chemical and liquid food segments experienced declines [19] - The target price has been raised to HKD 8.40, maintaining a buy rating [19] Group 11: Fuyao Glass - The company faced a revenue decline of 26% in Q2 2025, with a significant asset impairment charge [20] - The photovoltaic glass industry is expected to rebound due to reduced production and increased demand [20] - The target price has been slightly adjusted to HKD 11.70, reflecting a positive outlook on valuation [20] Group 12: Jingneng Clean Energy - The company reported a 5% decline in profit for the first half of 2025, but operating profit increased by 10% after adjusting for one-time items [21] - The company plans to adjust its renewable energy installation forecasts for 2025-2027 [22] - The target price has been raised to HKD 3.12, indicating a strong dividend yield [22]

Group 1 - The core viewpoint of the report is that Citi has downgraded the revenue forecast for Jinxin Reproductive (01951) for 2025 to 2027 by 12% to 20% and the net profit forecast by 27% to 31%, expecting a net loss in 2025 [1] - Jinxin's revenue decreased by 11% in the first half of the year, resulting in a net loss of 1 billion RMB, primarily due to impairment of overseas assets [1] - The company believes that all headwinds have dissipated in the first half of the year and expects improvement in the second half compared to the first half [1] Group 2 - Citi maintains a neutral outlook for Jinxin in 2025 but anticipates a return to positive performance in 2026 and 2027 [1] - According to the revised forecast, Jinxin's revenue is expected to decline by 4% in 2025, recover by 10% in 2026, and continue to rise by 14% in 2027 [1] - The target price for Jinxin has been adjusted from 3.8 HKD to 3.5 HKD based on the revised forecasts and a higher target price-to-earnings ratio [1]

Group 1 - The core viewpoint of the report is that Jefferies has downgraded its revenue forecasts for Jinxin Reproductive (01951) for 2025 to 2027 by 12% to 20% and net profit forecasts by 27% to 31%, anticipating a net loss in 2025 due to cautious outlook and performance in the first half of 2025 [1] - Jinxin Reproductive reported an 11% decline in revenue for the first half of the year, resulting in a net loss of 1 billion RMB, primarily due to impairment of overseas assets [1] - The company believes that all headwinds have dissipated in the first half of the year and expects improvement in the second half compared to the first half [1] Group 2 - Jefferies maintains a neutral outlook for Jinxin in 2025 but expects the company to return to positive growth in 2026 and 2027 [1] - According to the revised forecasts, Jefferies anticipates Jinxin's revenue to decline by 4% in 2025, followed by a recovery of 10% in 2026 and a further increase of 14% in 2027 [1] - The target price for Jinxin has been adjusted from 3.8 HKD to 3.5 HKD based on the revised forecasts and a higher target price-to-earnings ratio [1]

Core Viewpoint - The report from CICC indicates a downward adjustment in the net profit forecast for Jinxin Fertility (01951) for 2025-2026 due to the impact of medical insurance payment policies and zero markup on medical consumables, with a projected decrease of 59.9% and 7.5% to 170 million and 417 million yuan respectively, while maintaining an "outperform" rating and a target price of HKD 3.90, suggesting a potential upside of 25.0% from the current closing price [1][2]. Group 1 - Jinxin Fertility's 1H25 performance fell short of market expectations, reporting revenue of 1.289 billion yuan, a year-on-year decline of 10.7%, and an adjusted net profit of 82 million yuan, down 67.0% year-on-year, primarily due to the impact of medical insurance policies on cycle numbers and average transaction prices, as well as the execution of zero markup policies on drug costs [2][3]. - The company anticipates a recovery in 2026 as the impact of policies stabilizes, with a gradual return of patients to IVF services, alongside the expected capacity release from the new building in Shenzhen [3][5]. Group 2 - In 1H25, the company faced short-term pressure due to policy impacts, with a significant increase in the proportion of artificial insemination (IUI) cycles affecting average transaction prices and profit margins [3]. - The company reported a net loss attributable to shareholders of 1.04 billion yuan in 1H25, largely due to impairment losses on goodwill and intangible assets in the US HRC amounting to 950 million yuan, and other investment impairments [4]. - The company plans to enhance shareholder returns through a long-term share buyback program after optimizing leverage, while also focusing on asset liability risk release and liquidity assurance through business restructuring and overseas loan renewals [4]. Group 3 - The company is focusing on key business areas as supportive policies for fertility are expected to continue, with the implementation of child-rearing subsidy policies likely to boost fertility intentions and benefit the overall growth of the assisted reproduction industry [5]. - The potential for policy support in egg freezing services is anticipated, as this area has stronger customer retention and longer service cycles, which could become a new growth driver for the company [5]. - The company expects to start relocating its Shenzhen facility in Q1 2026, aiming for a business capacity of 12,000-15,000 cycles, while continuing to strengthen core assisted reproduction services in Yunnan and Wuhan [5].